The July 2026 PCAC Peptide Votes — FDA’s Advisory Panel Recommends Four Compounds Against Its Own Staff

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) did something the agency’s own scientists had recommended against: it voted to recommend four peptides — BPC-157, KPV, TB-500, and MOTS-c — for addition to the 503A Bulks List for pharmacy compounding. The FDA’s pre-meeting briefing documents had proposed the same conclusion for every one of the seven substances under review: do not list them. The panel recommended four of them anyway, on narrow votes, over the written objection of the agency’s reviewers. That tension — an advisory committee departing from FDA staff — is the story.

This article is a plain-English read of what the committee actually voted on, the recorded tallies, why the outcome diverged from the FDA’s own position, and — the part most coverage skips — why a compounding-eligibility vote does not touch the separate research-use-only (RUO) framework under which laboratory compounds are supplied. It is educational and regulatory in nature.

This article reflects the meeting record as of the morning of July 24, 2026. The July 23 (Day 1) votes are complete and reported below. The July 24 (Day 2) votes on Emideltide/DSIP, Semax, and Epitalon were still in progress at the time of writing and may post-date this publication; treat that section as provisional and confirm against the official FDA record.

This article is educational and regulatory in nature. It is not legal advice, and it makes no claim that any compound is approved, safe, or effective for human use. All compound references are in the context of in-vitro and preclinical laboratory research use only.

Section 1 — What the Committee Actually Voted (Day 1)

On Thursday, July 23, the PCAC took up the first four of seven peptides, each evaluated in both free base and acetate salt forms, and each for a specific proposed use rather than any blanket endorsement. According to reporting from multiple primary outlets covering the meeting, the recorded outcomes were:

• BPC-157 — evaluated for the indication of ulcerative colitis. Recommended for the 503A Bulks List on a vote of 8 in favor, 6 opposed, 1 abstention.
• KPV — evaluated for wound healing and inflammatory conditions. Recommended on the same 8-6, one-abstention split.
• TB-500 (thymosin beta-4 fragment) — evaluated for wound healing. Recommended on the same 8-6, one-abstention split.
• MOTS-c — evaluated for metabolic uses including obesity and osteoporosis. Recommended on a vote of 7 in favor, 5 opposed, 2 abstentions.

Two things are worth stating precisely. First, “recommended” here means the committee suggested the substance be considered for the list that licensed compounding pharmacies may draw on to prepare patient-specific prescriptions — not that it was approved, and not that it was found safe or effective. Second, each vote was tied to the specific evaluated indication named above. The committee did not endorse these peptides for general use, for research use, or for any purpose beyond the narrow compounding question in front of it.

The near-even margins matter as much as the direction. An 8-6 result with an abstention is not a mandate; it is a divided panel narrowly advancing a recommendation that the agency’s own written analysis opposed.

Section 2 — The Story: A Panel That Departed From FDA Staff

Ahead of the meeting, FDA staff posted a scientific review recommending against adding any of the seven peptides to the 503A Bulks List, citing a consistent set of concerns: the substances are not well physically and chemically characterized, there is little or no human evidence of effectiveness for the proposed (mostly injectable) routes, and there is insufficient human safety data, including unassessed immunogenicity risk. For BPC-157 specifically, the briefing package cited a “lack of evidence to support the effectiveness” of the compound for ulcerative colitis. During the meeting, an FDA reviewer pressed the characterization problem directly — asking, in effect, “What is BPC-157?” — and noting that quality standards cannot be established for a substance that is not yet well defined. Another FDA scientist agreed the peptide is “not well-characterized.” For TB-500, the agency noted it found no medical literature in which the peptide was administered to patients for any condition, and even pointed to an in-vitro study in which TB-500 did not induce wound healing in scratch-wounded fibroblast cultures.

The committee heard all of that and recommended four of the peptides anyway. Two dynamics explain the gap. The first is a philosophical divide about who should decide. PCAC member David Pope of XiFin Pharmacy Solutions summarized the “yes” rationale plainly: “I voted yes because it’s time to put this decision back in the hands of the physician and pharmacist.” The dissent was equally direct — member Elizabeth Rebello of MD Anderson Cancer Center pointed to the “lack of efficacy data and randomized controlled trials,” and member Bill Zamboni said there were “too many unknowns about this product.”

The second dynamic is the composition of the panel. In the weeks before the meeting, the FDA seated eight new PCAC members, several reported by multiple news outlets to have ties to prescribing or promoting peptides — conflicts that were reportedly the subject of internal FDA concern — along with additional temporary voting members just before the session. Reporting on the tallies noted that all eight new appointees voted in favor of BPC-157, KPV, and TB-500. The policy backdrop is also unusually visible: HHS Secretary Robert F. Kennedy Jr. has publicly described himself as a “big fan” of peptides and signaled an intent to loosen prior restrictions. None of this determines how any individual voted, but it is the context in which a staff recommendation was overridden, and honest coverage names it.

Section 3 — Day 2: The Remaining Three (Provisional)

The July 24 agenda covered the final three substances, again each in free base and acetate forms and each for a specific evaluated use: Emideltide / DSIP (delta sleep-inducing peptide, evaluated for opioid withdrawal, chronic insomnia, and narcolepsy), Semax (evaluated for cerebral ischemia, migraine, and trigeminal neuralgia), and Epitalon / Epithalon (evaluated for insomnia).

At the time of writing, the committee’s votes on these three had not yet been recorded in the public meeting materials, and the FDA’s written recommendation against all seven remains the documented staff position going in. Anyone reading a confident claim that DSIP, Semax, or Epitalon was “approved,” “rejected,” or “legalized” on a specific tally should trace it to the official FDA meeting record before believing it. This section will be superseded by that record; the responsible summary today is that the four Day 1 compounds received favorable recommendations, and the three Day 2 compounds were under a review in which the agency’s scientists urged rejection.

Section 4 — “Recommend” Is Not “Approve”: How Much This Decides

This is the distinction that separates careful reading from hype. Three things are true at once, and all three matter.

First, the PCAC’s recommendation is advisory and non-binding. Advisory committees advise. The FDA generally weighs their votes seriously, but it is not legally required to follow them — and the agency has periodically declined to follow its outside experts in the past. A favorable committee vote is a recommendation to the agency, not a decision by it.

Second, a vote is not a rule, and nothing was listed today. Even where the committee and the agency ultimately align, adding a substance to the 503A Bulks List proceeds through a formal FDA determination and notice-and-comment rulemaking in the Federal Register — a process that can take a year or more. No peptide’s status changed on July 23. No compound became newly available, newly approved, or newly “legal” because of the vote. The meeting is a step in a long process, not its conclusion.

Third, the underlying record was contested. The public comment docket (FDA-2025-N-6895) drew submissions from patient-access and compounding advocates pressing for inclusion and from safety organizations urging rejection of unapproved peptides on sourcing and safety grounds. The open public hearings featured physicians, public-health advocates, and peptide companies expressing sharply divergent views. Reporting has also indicated the FDA intends to bring additional peptides before the committee at a later date, so this is one chapter, not the whole book.

Section 5 — Why Nothing Changed Today for RUO Research Supply

Here is the distinction the loudest headlines keep collapsing, and it deserves to be stated directly. The 503A Bulks List governs compounding pharmacies preparing medications for individual patients under prescription. Research-use-only supply is a different framework entirely: compounds sold to qualified laboratories and researchers for in-vitro and preclinical work, explicitly not for human consumption, not as medicines, and not as compounded preparations.

Whatever the committee recommended, and whatever rule eventually follows, the practical consequences for RUO research supply are narrow:

• It does not make any compound “legal for human use.” A favorable compounding recommendation concerns pharmacy compounding under prescription — not FDA drug approval, and not research supply. None of these seven peptides is an FDA-approved drug, and the vote does not change that. It does not authorize anyone to consume a research material.
• It does not change RUO status, labeling, or permissible use. Research compounds are supplied for laboratory use only — not for human consumption, veterinary use, or diagnostic procedures. That status is a function of how the material is intended, labeled, and sold, and it is entirely unaffected by a compounding-eligibility vote.
• It does not lower the bar on verification. If anything, a period of heightened regulatory attention — and an FDA reviewer standing up to ask “what is this substance?” — is the strongest possible argument for demanding identity and purity data on every lot. The questions worth asking about any research material are the same before and after the vote: who tested it, by what methods, and whether the result is independently verifiable.

The most useful posture for a researcher is to treat the PCAC votes as meaningful context for the broader peptide landscape while recognizing that they operate in a lane that does not reach RUO research work.

Section 6 — How to Read the Coverage That Follows

A divided, headline-grabbing vote produces a wave of confident claims in both directions. A few source-evaluation habits keep the signal.

Trace it to a primary source. The FDA advisory committee page for the July 23–24, 2026 meeting, the individual briefing documents, the docket (FDA-2025-N-6895) on Regulations.gov, and any subsequent Federal Register entries are public. Reputable outlets that carried the tallies — including regulatory trade press and major national reporting — trace their claims to that record. A claim that cannot be traced to one of those is unverified.

Watch the verbs. “Recommended for inclusion” is not “approved.” “Voted to add” is not “legalized as a drug.” “Under review” is not “cleared.” A narrow 8-6 recommendation is not a mandate. Coverage that swaps these is coverage to distrust.

Separate the frameworks. Compounding eligibility, drug approval, and research-use-only supply are three different things. Any piece that treats a compounding vote as a verdict on whether you may research a compound — or as a signal that peptides are “becoming legal” — is mixing lanes the regulations keep separate.

Be wary of “legal now” marketing. Vendors have strong incentives to overstate the vote’s reach. A supplier using the result to imply human-use legitimacy — or to manufacture urgency around a purchase — is telling you more about its marketing than about the regulation.

Section 7 — What Comes Next

For the four peptides the committee recommended, the path forward runs through the FDA itself: the agency must decide whether to accept each recommendation and, if so, initiate the rulemaking that would formally place the substance on the 503A Bulks List. That is a determination the FDA has not made, and there is no fixed deadline by which it must. For the Day 2 compounds, the published meeting record and the committee’s final recommendations are the documents to watch, followed by whatever position the agency stakes out in response.

None of this alters the fact that these substances, as approved drug products, do not exist — none of the seven is FDA-approved, and a compounding recommendation is not approval. For the research community, the practical takeaway is continuity, not upheaval: the compounds studied in laboratories remain research materials governed by the RUO framework, and the regulatory contest over compounding eligibility, however consequential for pharmacies and prescribers, does not rewrite that boundary. (For the underlying framework, see our companion explainers on the pre-meeting PCAC briefing documents, the 2026 FDA peptide reclassification, and the peptide industry’s compliance landscape.)

Section 8 — The PYXAX Position and Verification Standard

PYXAX supplies research compounds strictly for in-vitro and preclinical laboratory use. Our position on the July 2026 PCAC votes is straightforward: they concern a pharmacy-compounding framework separate from research supply, their outcome runs through a rulemaking process that is not finished at the vote, and they do not change how research compounds are labeled, intended, or verified.

What does not change — regardless of any regulatory outcome — is the verification standard applied to every lot before listing.

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch. The analytical panel is consistent across the program:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin by the USP <85> LAL method
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number matching the COA in the PYXAX COA Library, which researchers can confirm independently before ordering. Select lots are submitted to Janoshik Analytical for community verification, with results searchable by batch number; founding batches were verified by Krause Analytical.

View COA Library →
Read The PYXAX Standard →
Browse Research Compounds →

For the authoritative status of this process, consult the FDA’s advisory committee page for the July 23–24, 2026 PCAC meeting and its published briefing documents, the meeting docket (FDA-2025-N-6895) on Regulations.gov, the Federal Register, and primary reporting from outlets such as Regulatory Focus (RAPS), STAT, NBC News, TIME, NPR, and BioPharma Dive. For the pre-meeting picture, see our companion explainer on the July 2026 PCAC briefing documents.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.